Imfinzi (Durvalumab)

Durvalumab is a monoclonal antibody that binds to the programmed death‑ligand 1 (PD‑L1) protein on tumour and immune cells. By blocking PD‑L1’s interaction with PD‑1 and CD80 receptors, it lifts the inhibition on T‑cells, allowing the immune system to recognise and attack cancer cells more effectively.

The specific dose and schedule of Imfinzi are determined by the prescribing oncologist based on the approved indication, patient weight, and clinical factors. Healthcare professionals follow the product’s prescribing information to calculate the appropriate infusion dose for each individual.

Safety data for Durvalumab in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It is generally recommended to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding decisions should be made in consultation with a healthcare provider.

To request Imfinzi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Imfinzi (Durvalumab) targets PD‑L1, similar to other PD‑L1 inhibitors, but differs from PD‑1 inhibitors such as pembrolizumab in its binding site. Clinical trials have shown comparable efficacy in certain lung and urothelial cancers, while safety profiles may vary slightly based on the specific immune‑related adverse events observed.

Imfinzi should be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and do not freeze or shake the solution. Maintaining the cold chain is essential to preserve product stability and efficacy.

Imfinzi is given as an intravenous infusion. The solution for infusion is administered by a qualified healthcare professional in a clinical setting, typically over a period of 60 minutes, with monitoring for infusion‑related reactions during and after the administration.

The most serious risks include immune‑mediated pneumonitis, hepatitis, colitis, severe endocrine disorders, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Prompt recognition and management of these events are critical, and treatment may need to be discontinued if severe toxicity occurs.

Patients with active uncontrolled autoimmune diseases, those receiving live vaccines, or individuals with a history of severe hypersensitivity to Durvalumab or any component of the formulation should not receive Imfinzi. Clinicians must evaluate each patient’s medical history before initiating therapy.